|
07.11.2024 15:50:51
|
Neurocrine's Ingrezza Shows Positive Data For Reduction Of Huntington's Disease Chorea
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX), Thursday announced data from the KINECT-HD study regarding the positive impact of Ingrezza capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease.
The company explained that people with Huntington's disease, a hereditary progressive neurodegenerative disorder, often suffer from chorea, an abnormal involuntary movement disorder.
During the phase 3 study, the effects of Ingrezza were compared to that of placebo using the Unified Huntington's Disease Rating Scale - Total Maximal Chorea score.
The findings revealed that the consistent efficacy of Ingrezza in reducing chorea across various subgroups and its potential positive impact on emotional health in patients.
Currently, Neurocrine's stock is trading at $126.32, up 0.82 percent on the Nasdaq.
Nachrichten zu Neurocrine Biosciences Inc.
Analysen zu Neurocrine Biosciences Inc.
3 Knaller-Aktien im BX Musterportfolio📈: Fiserv Inc., Cintas & Blackstone mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Fiserv Inc.
✅ Cintas
✅ Blackstone
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Neurocrine Biosciences Inc. | 134.83 | 7.74% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
SMI stabil -- DAX sinkt leicht -- Asiens Börsen mehrheitlich höherDer heimische Markt zeigt sich zur Wochenmitte wenig verändert. Der deutsche Leitindex präsentiert sich derweil moderat im Minus. An den Märkten in Fernost geht es am Mittwoch mehrheitlich nach oben.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |